Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28509589 | 0.88 | DRD4 (0.39) | SMN1; SMN2HSD17B10TP53POLBTSHR | |
| SCHEMBL21301988 | 0.86 | GBA1 (0.40) | GBA1TP53PDK2CHRM2CHRM4 | |
| SCHEMBL21302004 | 0.85 | CHRM2 (0.44) | PDK2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL21302005 | 0.85 | TP53 (0.39) | GBA1TP53LMNAPDK2CHRM2 | |
| SCHEMBL30516352 | 0.85 | DRD4 (0.43) | SMN1; SMN2HSD17B10TP53POLBTSHR | |
| SCHEMBL21291611 | 0.85 | DRD4 (0.43) | SMN1; SMN2HSD17B10TP53POLBTSHR | |
| SCHEMBL21301990 | 0.84 | NPSR1 (0.41) | SMN1; SMN2HSD17B10TP53TSHRPDK2 | |
| SCHEMBL21301981 | 0.82 | MAPK1 (0.47) | SMN1; SMN2TP53PDK2CHRM2CHRM4 | |
| SCHEMBL21301993 | 0.82 | S1PR3 (0.39) | SMN1; SMN2TP53PDK2CHRM2CHRM4 | |
| SCHEMBL31066766 | 0.82 | S1PR3 (0.39) | SMN1; SMN2TP53PDK2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2025-06-03 | — | — | US | disclosed |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed Pharma S.A (PL) | 2024-08-29 | — | — | US | disclosed |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2024-05-14 | — | — | US | disclosed |
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | disclosed |
| US-20210276995-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2021-09-09 | — | — | US | disclosed |
| US-20210276995-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2021-09-09 | — | — | US | disclosed |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2021-06-15 | — | — | US | disclosed |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2021-06-15 | — | — | US | disclosed |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | ACADIA PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | ACADIA PHARMACEUTICALS INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019162306-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2019-08-29 | — | — | WO | disclosed |
| EP-3530651-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed sp. z o.o. (PL) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | SMN1; SMN2 3365/4885HSD17B10 3842/4885GBA1 3238/4885 |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR2C, HTR6 | SMN1; SMN2 2781/4885HSD17B10 4161/4885GBA1 2381/4885 |
| US-11034688-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | SMN1; SMN2 3365/4885HSD17B10 3842/4885GBA1 3238/4885 |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR6, HTR2C | SMN1; SMN2 3307/4885HSD17B10 3840/4885GBA1 3273/4885 |
| US-20200377496-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR6, HTR2C | SMN1; SMN2 3365/4885HSD17B10 3842/4885GBA1 3238/4885 |
| US-20210276995-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR2C, HTR6 | SMN1; SMN2 2781/4885HSD17B10 4161/4885GBA1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.